Investor Presentaiton

Strong track record Unique model Large moat Significant opportunity Compounding growth Growth outlook has accelerated with strong business momentum Adjusted Cash Receipts (¹) ("top-line") 2020-2025e CAGR outlook 6-9% At IPO (June 2020) ROYALTY PHARMA 7-10% Corporate update (February 2021) 11-14% Today (May 2022) Increasing long-term CAGR target by ~50% versus midpoint of previous range 1. See slide 114 for definitions and factors that may impact the achievement of our growth outlook. Growth outlook includes future royalty acquisitions and excludes development-stage pipeline candidate gantenerumab for Alzheimer's disease. Refer to the Appendix for a GAAP to non-GAAP reconciliation. 22 22

View entire presentation